Pulmonx Research and Development Expenses 2019-2024 | LUNG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Pulmonx research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Pulmonx Research and Development Expenses 2019-2024 | LUNG

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Pulmonx research and development expenses from 2019 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.

Related Stocks
Company Name	Market Cap
GE HealthCare Technologies (GEHC)	$40.4B
Tempus AI (TEM)	$7.9B
Inspire Medical Systems (INSP)	$6.2B
Axonics (AXNX)	$3.5B
Hims & Hers Health (HIMS)	$3.5B
10x Genomics (TXG)	$2.7B
Enovis (ENOV)	$2.4B
Azenta (AZTA)	$2.4B
Privia Health (PRVA)	$2.3B
IRhythm Technologies (IRTC)	$2.2B
Omnicell (OMCL)	$2B
Clover Health Investments (CLOV)	$1.5B
Schrodinger (SDGR)	$1.4B
Phreesia (PHR)	$1.4B
Standard BioTools (LAB)	$753M
Fulgent Genetics (FLGT)	$694M
Definitive Healthcare (DH)	$538M
Health Catalyst (HCAT)	$529M
Butterfly Network (BFLY)	$406M
Talkspace (TALK)	$343M
SOPHiA GENETICS SA (SOPH)	$286M
TruBridge (TBRG)	$183M
P3 Health Partners (PIII)	$165M
American Well (AMWL)	$147M
Augmedix (AUGX)	$115M
EUDA Health Holdings (EUDA)	$90M
Future Health ESG (FHLT)	$65M
SHL Telemedicine (SHLT)	$55M
HeartBeam (BEAT)	$53M
111 (YI)	$51M